Clinical Trial Update: Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating apatinib plus irinotecan as a second-line treatment for metastatic gastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Adenocarcinoma

Drugs mentioned

• apatinib + irinotecan

Snippet

Sponsor: China Medical University, China | Conditions: Metastatic Gastric Adenocarcinoma | Phase 2 | Status: UNKNOWN